Patents by Inventor Franck Pages

Franck Pages has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12291752
    Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.
    Type: Grant
    Filed: December 27, 2021
    Date of Patent: May 6, 2025
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)
    Inventors: Jerome Galon, Franck Pages, Bernard Mlecnik, Gabriela Bindea
  • Publication number: 20220308063
    Abstract: The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer.
    Type: Application
    Filed: March 4, 2022
    Publication date: September 29, 2022
    Inventors: Jerome Galon, Franck Pages, Wolf-Herman Fridman
  • Patent number: 11300569
    Abstract: The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 12, 2022
    Assignees: ISERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (APHP)
    Inventors: Jerome Galon, Franck Pages, Wolf-Herman Fridman
  • Patent number: 11242564
    Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: February 8, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE PARIS, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Jerome Galon, Franck Pages, Bernard Mlecnik, Gabriela Bindea
  • Publication number: 20200299784
    Abstract: A method for screening patients with a cancer comprising i) determining in a tumor sample obtained from a patient an expression level ELA1-ELAn of one or several genes GA1-GAn representative of human adaptive immune response and an expression level ELI1-ELIn of one or several genes GI1-GIn representative of human immunosuppressive response, ii) comparing the expression levels ELA1-ELAn and ELI1-ELIn determined at step i) with predetermined reference values ELRA1-ELRAn and ELRI1-ELRIn selected such as said predetermined reference values separate a panel of patients with a cancer into two groupings according to the expression level of said genes and to survival of patients according to Kaplan Meier curves analyses and associated logrank p values iii) concluding whether the patient has a good (level higher than the predetermined reference value) or a bad (level lower than the predetermined reference value) adaptive immune response and a good or a bad immunosuppressive response, optionally further comprising a st
    Type: Application
    Filed: June 9, 2020
    Publication date: September 24, 2020
    Inventors: Jerome Galon, Franck Pages, Bernhard Milecnik, Gabriela Bindea
  • Publication number: 20200248269
    Abstract: The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient.
    Type: Application
    Filed: December 2, 2019
    Publication date: August 6, 2020
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Inventors: Jerome Galon, Franck Pages, Bernhard MLECNIK, Herve FRIDMAN
  • Publication number: 20190178892
    Abstract: The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 13, 2019
    Inventors: Jerome Galon, Franck Pages, Wolf-Herman Fridman
  • Patent number: 10317408
    Abstract: A method for assessment of a number or density of immune cells in tumoral tissues comprising the steps consisting in: a. providing one or more immunostained slices of tissue section obtained by an automated slide-staining system by using antibodies binding specifically to antigens (markers) expressed by immune cells. b. proceeding to digitalization of the slides of step a. by high resolution scan capture, whereby a high definition (4.6 ?m/pixel or better) digital picture of the slide to be analyzed is obtained, c. detecting the slice of tissue section on the digital picture d. analyzing the slice of tissue section for defining (i) the tumor (CT) and (ii) the invasive margin of the tumor (IM), e. providing a size reference grid with uniformly distributed units having a same surface, said grid being adapted to the size of the tumor to be analyzed, e1. checking the quality of immunostaining, f.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: June 11, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris Descartes, Assistance Publique-Hopitaux de Paris
    Inventors: Jerome Galon, Franck Pages, Bernhard Mlecnik
  • Patent number: 10191059
    Abstract: The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: January 29, 2019
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Descartes
    Inventors: Jerome Galon, Franck Pages, Wolf-Herman Fridman
  • Patent number: 9945861
    Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising the steps consisting of i) determining the density of B cells at the invasive margin of the tumor (im) in a tumor tissue sample obtained from said patient, ii) comparing said density with a predetermined reference value and iii) providing a good prognosis when the density of B cells at the invasive margin of the tumor is higher than the predetermined reference value and a poor prognosis when the density of B cells at the invasive margin of the tumor is lower than the predetermined reference value.
    Type: Grant
    Filed: January 21, 2013
    Date of Patent: April 17, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Jerome Galon, Franck Pages, Bernhard Mlecnik, Gabriela Bindea, Herve Fridman
  • Publication number: 20170175207
    Abstract: The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient.
    Type: Application
    Filed: March 1, 2017
    Publication date: June 22, 2017
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Inventors: Jerome Galon, Franck Pages, Bernhard MLECNIK, Herve FRIDMAN
  • Patent number: 9645152
    Abstract: The present invention provides methods and kits for the prognosis of survival time of a patient suffering from a cancerous tumor. The method involves quantitating the density of Th17 cells at the center of the tumor and at the invasive margin of the tumor, where low density values at each location indicate a favourable prognosis, high values at each location indicate an unfavourable prognosis, and heterogeneous values at the two locations (one high, one low) indicate an intermediate prognosis.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: May 9, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Descartes—Paris V, Assistance Publique—Hopitaux de Paris
    Inventors: Jerome Galon, Franck Pages, Herve Fridman, Bernhard Mlecnik
  • Publication number: 20150268245
    Abstract: The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer.
    Type: Application
    Filed: May 20, 2015
    Publication date: September 24, 2015
    Inventors: Jerome Galon, Franck Pages, Wolf-Herman Fridman
  • Publication number: 20150225799
    Abstract: The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient.
    Type: Application
    Filed: April 24, 2015
    Publication date: August 13, 2015
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Inventors: Jerome Galon, Franck Pages, Bernhard MLECNIK, Herve FRIDMAN
  • Publication number: 20150218650
    Abstract: A method for screening patients with a cancer comprising i) determining in a tumor sample obtained from a patient an expression level ELA1-ELAn of one or several genes GA1-GAn representative of human adaptive immune response and an expression level ELI1-ELIn of one or several genes Gl1-GIn representative of human immunosuppressive response, ii) comparing the expression levels ELA1-ELAn and ELI1-ELIn determined at step i) with predetermined reference values ELRA1-ELRAn and ELRI1-ELRIn selected such as said predetermined reference values separate a panel of patients with a cancer into two groupings according to the expression level of said genes and to survival of patients according to Kaplan Meier curves analyses and associated logrank p values iii) concluding whether the patient has a good (level higher than the predetermined reference value) or a bad (level lower than the predetermined reference value) adaptive immune response and a good or a bad immunosuppressive response, optionally further comprising a st
    Type: Application
    Filed: August 5, 2013
    Publication date: August 6, 2015
    Inventors: Jerome Galon, Franck Pages, Bernhard Mlecnik, Gabriela Bindea
  • Publication number: 20150203919
    Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.
    Type: Application
    Filed: July 12, 2013
    Publication date: July 23, 2015
    Inventors: Jerome Galon, Franck Pages, Bernard Mlecnik, Gabriela Bindea
  • Publication number: 20150153349
    Abstract: A method for assessment of a number or density of immune cells in tumoral tissues comprising the steps consisting in: a. providing one or more immunostained slices of tissue section obtained by an automated slide-staining system by using antibodies binding specifically to antigens (markers) expressed by immune cells. b. proceeding to digitalisation of the slides of step a. by high resolution scan capture, whereby a high definition (4.6 ?m/pixel or better) digital picture of the slide to be analysed is obtained, c. detecting the slice of tissue section on the digital picture d. analyzing the slice of tissue section for defining (i) the tumour (CT) and (ii) the invasive margin of the tumour (IM), e. providing a size reference grid with uniformly distributed units having a same surface, said grid being adapted to the size of the tumour to be analyzed, e1. checking the quality of immunostaining, f.
    Type: Application
    Filed: June 14, 2013
    Publication date: June 4, 2015
    Inventors: Jerome Galon, Franck Pages, Bernhard Mlecnik
  • Publication number: 20140363472
    Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising the steps consisting of i) determining the density of B cells at the invasive margin of the tumor (im) in a tumor tissue sample obtained from said patient, ii) comparing said density with a predetermined reference value and iii) providing a good prognosis when the density of B cells at the invasive margin of the tumor is higher than the predetermined reference value and a poor prognosis when the density of B cells at the invasive margin of the tumor is lower than the predetermined reference value.
    Type: Application
    Filed: January 21, 2013
    Publication date: December 11, 2014
    Inventors: Jerome Galon, Franck Pages, Bernhard Mlecnik, Gabriela Bindea, Herve Fridman
  • Publication number: 20140057257
    Abstract: The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer.
    Type: Application
    Filed: June 4, 2013
    Publication date: February 27, 2014
    Inventors: Jerome Galon, Franck Pages, Wolf-Herman Fridman
  • Publication number: 20140018255
    Abstract: The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient.
    Type: Application
    Filed: January 11, 2012
    Publication date: January 16, 2014
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, UNIVERSITE PARIS DESCARTES
    Inventors: Jérôme Galon, Franck Pages, Bernhard Mlecnik, Herve Fridman